Non-Current Assets
Equity Method Investments
Pfizer Equity Method Investments decreased by 89.5% to $223.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 97.9%, from $10.76B to $223.00M. Over 4 years (FY 2020 to FY 2024), Equity Method Investments shows a downward trend with a -66.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
Detailed definition
These are investments in entities where the company exercises significant influence but does not have full control. The...
Peer comparison
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
Metric ID:
equity_method_investmentsHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $20.94B | $21.60B | $16.47B | $20.74B | $18.96B | $13.89B | $11.03B | $14.74B | $15.07B | $14.24B | $11.64B | $11.61B | $11.15B | $10.76B | $217.00M | $2.01B | $2.12B | $223.00M |
| QoQ Change | — | +3.1% | -23.7% | +25.9% | -8.6% | -26.8% | -20.6% | +33.6% | +2.2% | -5.5% | -18.3% | -0.2% | -4.0% | -3.5% | -98.0% | +828.1% | +5.3% | -89.5% |
| YoY Change | — | — | — | — | -9.5% | -35.7% | -33.0% | -28.9% | -20.5% | +2.5% | +5.5% | -21.2% | -26.0% | -24.4% | -98.1% | -82.7% | -81.0% | -97.9% |
Range$217.00M – $21.60B
CAGR-65.7%
Avg YoY Growth-39.4%
Median YoY Growth-27.5%
Equity Method Investments at Other Companies
Frequently Asked Questions
- What is Pfizer's equity method investments?
- Pfizer (PFE) reported equity method investments of $223.00M in Q3 2025.
- How has Pfizer's equity method investments changed year-over-year?
- Pfizer's equity method investments decreased by 97.9% year-over-year, from $10.76B to $223.00M.
- What is the long-term trend for Pfizer's equity method investments?
- Over 4 years (2020 to 2024), Pfizer's equity method investments has grown at a -66.3% compound annual growth rate (CAGR), from $16.86B to $217.00M.
- What does equity method investments mean?
- The value of investments in other companies where the firm has significant influence but not total control.